Generic entry timeline

FERRIC OXYHYDROXIDE generics — when can they launch?

FERRIC OXYHYDROXIDE (FERRIC OXYHYDROXIDE) · · 22 active US patents · 0 expired

Earliest patent expiry
2028-11-13
2 years remaining
Full patent estate to
2035-05-26
complete protection through 2035
FDA approval
1982

Where FERRIC OXYHYDROXIDE sits in the generic timeline

Imminent generic cliff: earliest active US patent for FERRIC OXYHYDROXIDE expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Other — 11 patents
  • Formulation — 10 patents
  • Method of Use — 1 patent

FDA U-codes carved out by FERRIC OXYHYDROXIDE patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-1468(no description)

Sample patent estate

Showing 6 of 22 active US patents. View full estate on the FERRIC OXYHYDROXIDE drug page →

  • US10925896 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain high-loading iron oxy-hydroxide.
    USPTO title: Pharmaceutical compositions
  • US10925897 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain high-loading iron oxy-hydroxide.
    USPTO title: Pharmaceutical compositions
  • US10682376 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain high-loading iron oxy-hydroxide.
    USPTO title: Pharmaceutical compositions
  • US11013761 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain iron oxy-hydroxide in high loading.
    USPTO title: Pharmaceutical compositions
  • US10933090 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain high-loading iron oxy-hydroxide.
    USPTO title: Pharmaceutical compositions
  • US11013762 Formulation · expires 2028-11-13
    This patent protects pharmaceutical compositions for oral administration that contain high-loading iron oxy-hydroxide.
    USPTO title: Pharmaceutical compositions

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on FERRIC OXYHYDROXIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →